Granisetron Hikma (Granisetron)

Granisetron Hikma is prescribed to reduce nausea and vomiting in several clinical situations.

• Prevention of acute and delayed chemotherapy‑induced nausea and vomiting (CINV).
• Prevention of postoperative nausea and vomiting (PONV) after general anesthesia.
• Adjunct therapy for radiation‑induced nausea when chemotherapy is combined.
• Use in patients who have not responded adequately to other antiemetics.
• Management of nausea associated with diagnostic procedures involving emetogenic agents.

The safety profile of Granisetron Hikma includes both frequent mild reactions and rare serious events.

Common

• Headache, often mild and transient.
• Constipation or reduced bowel movements.
• Fatigue or feeling of tiredness.
• Dizziness or light‑headed sensation.
• Mild pain or erythema at the injection site.

Serious

• Anaphylactic reaction, including rash, swelling, or breathing difficulty.
• Cardiac rhythm disturbances such as QT interval prolongation.
• Serotonin syndrome when used with other serotonergic drugs, presenting with agitation, hyperreflexia, or fever.
• Severe hypotension or shock.

Before prescribing Granisetron Hikma, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with known cardiac conduction disorders or prolonged QT interval.
• Evaluate renal or hepatic impairment, as dose adjustment may be required.
• Avoid use in patients receiving other serotonergic agents without monitoring.
• Monitor for signs of severe allergic reaction during and after infusion.
• Consider fetal risk; use only if potential benefit justifies potential risk.

Granisetron Hikma can interact with other medications; awareness of these interactions helps prevent adverse effects.

Avoid

• Concomitant use with other 5‑HT3 antagonists (e.g., ondansetron) due to additive antiemetic effect and unclear safety.
• Co‑administration with potent CYP3A4 inducers that may reduce granisetron exposure.

Use with caution

• Serotonergic drugs such as SSRIs, SNRIs, or tramadol, which may increase risk of serotonin syndrome.
• Medications that prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Drugs affecting cardiac conduction, requiring ECG monitoring.